In this study, the authors show that oral propranolol effectively treats infantile hemangiomas in 60% of participants compared to 4% with placebo in a randomized controlled trial.
Level of Evidence: Randomized Controlled Trial
Background: Infantile hemangiomas are benign vascular tumors affecting 5-10% of infants. Oral propranolol is a potential treatment option.
Methods: A double-blind, randomized trial compared oral propranolol (3 mg/kg/day) to placebo in 460 infants with hemangioma.
Results: Propranolol achieved successful treatment in 60% of participants, compared to 4% in the placebo group.
Conclusion: Oral propranolol is an effective and well-tolerated treatment for infantile hemangiomas, but further research is needed for optimal treatment duration and long-term effects.